SBI Securities’s Avadel Pharmaceuticals AVDL Stock Holding History

SBI Securities’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20	Closed	-$431	–	4032
2025 Q4	$431	Sell	20 -5	-20%	-$97	﹤0.01%	2920
2025 Q3	$382	Sell	25 -26	-51%	-$338	﹤0.01%	3080
2025 Q2	$451	Buy	51 +38	+292%	+$334	﹤0.01%	3004
2025 Q1	$102	Buy	13 +4	+44%	+$33	﹤0.01%	3431
2024 Q4	$95	Buy	+9	New	+$109	﹤0.01%	3469

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

SBI Securities's AVDL Position: Q1 2026 in Review

SBI Securities sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 20 shares — an estimated $431 sold.

SBI Securities first reported a position in AVDL in Q4 2024 and held it in 5 quarters. The position peaked at $451 in Q2 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

SBI Securities reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
SBI Securities sold 20 Avadel Pharmaceuticals shares in Q1 2026, an estimated $431.
SBI Securities first reported a position in Avadel Pharmaceuticals in Q4 2024 and held it in 5 quarters.
SBI Securities's Avadel Pharmaceuticals position peaked at $451 in Q2 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.